Sunovion Receives FDA Letter Advancing Regulatory Status of SUN-101/eFlow Therapy to Treat COPD
Sunovion Pharmaceuticals has received a complete response letter from the U.S. Food and Drug Administration (FDA), clearing the Massachusetts company from having to conduct further clinical trials for approval of its SUN-101/eFlow (glycopyrrolate) therapy to treat chronic obstructive pulmonary disease (COPD). According to a corporate press release, the CRL clears Sunovion…